Literature DB >> 7539865

c-met proto-oncogene expression in benign and malignant human prostate tissues.

L L Pisters1, P Troncoso, H E Zhau, W Li, A C von Eschenbach, L W Chung.   

Abstract

Previously, we demonstrated that hepatocyte growth factor/scatter factor (HGF/SF) is expressed by human bone stromal cells and is a powerful mitogen to prostatic epithelial cells in culture. Based on these observations, we hypothesized that, if prostate cancer cells in the prostate or bone environment respond to HGF/SF as a mitogen, then they must express the HGF/SF receptor, which is coded by the c-met proto-oncogene. We used immunohistochemical techniques to: 1) assess the presence and localization of c-met protein in benign and malignant human prostate tissues and 2) correlate the presence of c-met protein with tumor stage, grade and androgen sensitivity. c-met protein immunostaining was consistently observed in the basal epithelial layer of normal prostate glands but was absent in luminal epithelial cells of the peripheral and transition zones. c-met protein immunostaining was detected in 10 of 11 foci (91%) of high grade prostatic intraepithelial neoplasia (PIN). Overall, c-met protein staining was noted in 36 of 43 (84%) primary prostate cancer samples versus 2 of 11 (18%) benign prostate hyperplasia samples (p < 0.0001) and in 4 of 4 (100%) lymph node metastases, 23 of 23 (100%) bone marrow metastases and 1 of 3 (33%) other metastatic sites. There was a clear relationship between c-met protein staining and higher grade adenocarcinomas (p < 0.001). c-met protein is frequently detected in PIN and higher grade prostate cancers; future studies should evaluate the biological significance of these findings.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539865

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  60 in total

1.  Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

Authors:  Gary E Gallick; Paul G Corn; Amado J Zurita; Sue-Hwa Lin
Journal:  Future Med Chem       Date:  2012-01       Impact factor: 3.808

2.  Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.

Authors:  Jiaqi Mi; Erika Hooker; Steven Balog; Hong Zeng; Daniel T Johnson; Yongfeng He; Eun-Jeong Yu; Huiqing Wu; Vien Le; Dong-Hoon Lee; Joseph Aldahl; Mark L Gonzalgo; Zijie Sun
Journal:  J Biol Chem       Date:  2018-11-06       Impact factor: 5.157

Review 3.  Prostate epithelial differentiation is dictated by its surrounding stroma.

Authors:  L W Chung; R Davies
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

4.  Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer.

Authors:  R E Reiter; Z Gu; T Watabe; G Thomas; K Szigeti; E Davis; M Wahl; S Nisitani; J Yamashiro; M M Le Beau; M Loda; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

5.  MicroRNA-101-3p suppresses proliferation and migration in hepatocellular carcinoma by targeting the HGF/c-Met pathway.

Authors:  Yang Liu; Juan Tan; Shuangyan Ou; Jun Chen; Limin Chen
Journal:  Invest New Drugs       Date:  2019-03-30       Impact factor: 3.850

6.  Expression of the c-Met Proteins in Malignant Skin Cancers.

Authors:  Yoon-Jin Lee; Dae-Hyun Kim; Sang-Han Lee; Dong-Wook Kim; Hae-Seon Nam; Moon Kyun Cho
Journal:  Ann Dermatol       Date:  2011-02-28       Impact factor: 1.444

7.  p63 is a prostate basal cell marker and is required for prostate development.

Authors:  S Signoretti; D Waltregny; J Dilks; B Isaac; D Lin; L Garraway; A Yang; R Montironi; F McKeon; M Loda
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

8.  Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.

Authors:  Jinlu Dai; Honglai Zhang; Andreas Karatsinides; Jill M Keller; Kenneth M Kozloff; Dana T Aftab; Frauke Schimmoller; Evan T Keller
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

9.  Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R.

Authors:  Koh-Ichi Nakashiro; Shingo Hara; Yuji Shinohara; Miho Oyasu; Hitoshi Kawamata; Satoru Shintani; Hiroyuki Hamakawa; Ryoichi Oyasu
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

10.  Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells.

Authors:  Shumin Zhang; Haiyen E Zhau; Adeboye O Osunkoya; Shareen Iqbal; Xiaojian Yang; Songqing Fan; Zhengjia Chen; Ruoxiang Wang; Fray F Marshall; Leland W K Chung; Daqing Wu
Journal:  Mol Cancer       Date:  2010-01-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.